Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416411 | 0.93 | ACHE (0.40) | ACHEKMT2ASMN1; SMN2PPARGPPARA | |
| SCHEMBL13417055 | 0.88 | ACHE (0.40) | ACHELTA4HFFAR1 | |
| SCHEMBL13416257 | 0.88 | ACHE (0.43) | ACHEKMT2ASLC7A5 | |
| SCHEMBL13416420 | 0.85 | FFAR1 (0.37) | LTA4HFFAR1 | |
| SCHEMBL13416281 | 0.83 | ACHE (0.44) | ACHELTA4H | |
| SCHEMBL13416630 | 0.82 | LTA4H (0.39) | ACHELTA4HFFAR1PPARGPPARA | |
| SCHEMBL13396490 | 0.81 | ALOX5 (0.40) | ACHEKMT2ASMN1; SMN2LTA4HFFAR1 | |
| SCHEMBL13416241 | 0.81 | ACHE (0.41) | ACHEPPARGPPARAFDFT1 | |
| SCHEMBL13416274 | 0.81 | ACHE (0.44) | ACHE | |
| SCHEMBL13416453 | 0.80 | ACHE (0.41) | ACHEPPARGPPARAFDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
| WO-2008095841-A2 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | ACHE 540/4885KMT2A 4459/4885SMN1; SMN2 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.